Published in Oncology Business Week, January 31st, 2010
In this open-label, single-arm, Simon-design two-stage Phase II study entitled 'SAPHIRE', resminostat will be given orally at a dose of 600mg daily for five consecutive days, followed by a nine day treatment free period ('5+9' dosing schedule). In the main phase of the trial, patients will receive treatment for six cycles (12 weeks)....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week